Abbeduto, L., Berry-Kravis, E., Sterling, A., Sherman, S., Edgin, J. O., McDuffie, A., Hoffmann, A., Hamilton, D., Nelson, M., Aschkenasy, J., & Thurman, A. J. (2020). Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: Feasibility, practice effects, test-retest reliability, and construct validity. Journal of Neurodevelopmental Disorders, 12(1), 10. https://doi.org/10.1186/s11689-020-09313-6

Article  PubMed  PubMed Central  Google Scholar 

Anderson, C. C., Marentette, J. O., Prutton, K. M., Rauniyar, A. K., Reisz, J. A., D’Alessandro, A., Maclean, K. N., Saba, L. M., & Roede, J. R. (2021). Trisomy 21 results in modest impacts on mitochondrial function and central carbon metabolism. Free Radical Biology & Medicine, 172, 201–212. https://doi.org/10.1016/j.freeradbiomed.2021.06.003

Article  Google Scholar 

Andronis, C., Sharma, A., Virvilis, V., Deftereos, S., & Persidis, A. (2011). Literature mining, ontologies and information visualization for drug repurposing. Briefings in Bioinformatics, 12(4), 357–368. https://doi.org/10.1093/bib/bbr005

Article  PubMed  Google Scholar 

Antonaros, F., Lanfranchi, S., Locatelli, C., Martelli, A., Olivucci, G., Cicchini, E., Carosi Diatricch, L., Mannini, E., Vione, B., Feliciello, A., Ramacieri, G., Onnivello, S., Vianello, R., Vitale, L., Pelleri, M. C., Strippoli, P., Cocchi, G., Pulina, F., Piovesan, A., & Caracausi, M. (2021). One-carbon pathway and cognitive skills in children with Down syndrome. Science and Reports, 11(1), 4225. https://doi.org/10.1038/s41598-021-83379-7

Article  Google Scholar 

Aschenbrenner, A. J., Baksh, R. A., Benejam, B., Beresford-Webb, J. A., Coppus, A., Fortea, J., Handen, B. L., Hartley, S., Head, E., & Jaeger, J. (2021). Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 13(1), e12184.

Google Scholar 

Barbiero, I., Bianchi, M., & Kilstrup-Nielsen, C. (2022a). Therapeutic potential of pregnenolone and pregnenolone methyl ether on depressive and CDKL5 deficiency disorders: Focus on microtubule targeting. Journal of Neuroendocrinology, 34(2), e13033. https://doi.org/10.1111/jne.13033

Article  PubMed  Google Scholar 

Barbiero, I., Zamberletti, E., Tramarin, M., Gabaglio, M., Peroni, D., De Rosa, R., Baldin, S., Bianchi, M., Rubino, T., & Kilstrup-Nielsen, C. (2022b). Pregnenolone-methyl-ether enhances CLIP170 and microtubule functions improving spine maturation and hippocampal deficits related to CDKL5 deficiency. Human Molecular Genetics, 31(16), 2738–2750. https://doi.org/10.1093/hmg/ddac067

Article  PubMed  Google Scholar 

Berry-Kravis, E. (2022). Disease-targeted treatment translation in fragile X Syndrome as a model for neurodevelopmental disorders. Journal of Child Neurology, 37(10–11), 797–812. https://doi.org/10.1177/08830738221089740

Article  PubMed  Google Scholar 

Caracausi, M., Ghini, V., Locatelli, C., Mericio, M., Piovesan, A., Antonaros, F., Pelleri, M. C., Vitale, L., Vacca, R. A., Bedetti, F., Mimmi, M. C., Luchinat, C., Turano, P., Strippoli, P., & Cocchi, G. (2018). Plasma and urinary metabolomic profiles of Down syndrome correlate with alteration of mitochondrial metabolism. Science and Reports, 8(1), 2977. https://doi.org/10.1038/s41598-018-20834-y

Article  Google Scholar 

Carmona-Iragui, M., Alcolea, D., Barroeta, I., Videla, L., Munoz, L., Van Pelt, K. L., Schmitt, F. A., Lightner, D. D., Koehl, L. M., Jicha, G., Sacco, S., Mircher, C., Pape, S. E., Hithersay, R., Clare, I. C. H., Holland, A. J., Nubling, G., Levin, J., Zaman, S. H., … Fortea, J. (2021). Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: A cohort study. Lancet Neurology, 20(8), 605–614. https://doi.org/10.1016/S1474-4422(21)00129-0

Article  PubMed  Google Scholar 

Costa, A. C. S., Brandao, A. C., Boada, R., Barrionuevo, V. L., Taylor, H. G., Roth, E., Stasko, M. R., Johnson, M. W., Assir, F. F., Roberto, M. P., Salmona, P., Abreu-Silveira, G., Bederman, I., Prendergast, E., Huls, A., Abrishamcar, S., Mustacchi, Z., Scheidemantel, T., Roizen, N. J., & Ruedrich, S. (2022). Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, 21(1), 31–41. https://doi.org/10.1016/S1474-4422(21)00369-0

Article  PubMed  Google Scholar 

Del Hoyo Soriano, L., Bullard, L., Thurman, A. J., Alvarez, C. H., & Abbeduto, L. (2022). Providing a parent-administered outcome measure in a bilingual family of a father and a mother of two adolescents with ASD: Brief report. Developmental Neurorehabilitation, 25(2), 140–144. https://doi.org/10.1080/17518423.2021.1942281

Article  PubMed  Google Scholar 

Diaz-Caneja, C. M., State, M. W., Hagerman, R. J., Jacquemont, S., Marin, O., Bagni, C., Umbricht, D., Simonoff, E., de Andres-Trelles, F., Kaale, A., Pandina, G., Gomez-Mancilla, B., Wang, P. P., Cusak, J., Siafis, S., Leucht, S., Parellada, M., Loth, E., Charman, T., … Arango, C. (2021). A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. European Neuropsychopharmacology, 48, 49–88. https://doi.org/10.1016/j.euroneuro.2021.02.020

Article  PubMed  Google Scholar 

Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d’Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., Rafii, M. S., Krinsky-McHale, S. J., Urv, T., & Outcome Measures Working, G (2017). Outcome measures for clinical trials in Down syndrome. American Journal on Intellectual and Developmental Disabilities, 122(3), 247–281. https://doi.org/10.1352/1944-7558-122.3.247

Article  PubMed  PubMed Central  Google Scholar 

Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E., Christian, B. T., Lai, F., Rosas, H. D., Schupf, N., Krinsky-McHale, S., Silverman, W., Lee, J. H., Klunk, W. E., Handen, B. L., Allegri, R. F., Lott, I. T., & Dominantly Inherited Alzheimer, N. (2021). Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer’s disease: A cross-sectional study. Lancet Neurology, 20(8), 615–626. https://doi.org/10.1016/S1474-4422(21)00139-3

Article  PubMed  Google Scholar 

Ferraro, L., Scala, G., Cerulo, L., Carosati, E., & Ceccarelli, M. (2023). MOViDA: multiomics visible drug activity prediction with a biologically informed neural network model. Bioinformatics, 39(7). https://doi.org/10.1093/bioinformatics/btad432

Firth, N. C., Startin, C. M., Hithersay, R., Hamburg, S., Wijeratne, P. A., Mok, K. Y., Hardy, J., Alexander, D. C., Consortium, L., & Strydom, A. (2018). Aging related cognitive changes associated with Alzheimer’s disease in Down syndrome. Annals of Clinical and Translational Neurology, 5(6), 741–751.

Article  PubMed  PubMed Central  Google Scholar 

Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., Askenazi, M., Wisniewski, T., Busciglio, J., & Cuello, A. C. (2020). Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain, 143(12), 3653–3671. https://doi.org/10.1093/brain/awaa326

Article  PubMed  PubMed Central  Google Scholar 

Fortea, J., Carmona-Iragui, M., Benejam, B., Fernandez, S., Videla, L., Barroeta, I., Alcolea, D., Pegueroles, J., Munoz, L., Belbin, O., de Leon, M. J., Maceski, A. M., Hirtz, C., Clarimon, J., Videla, S., Delaby, C., Lehmann, S., Blesa, R., & Lleo, A. (2018a). Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: A cross-sectional study. Lancet Neurology, 17(10), 860–869. https://doi.org/10.1016/S1474-4422(18)30285-0

Article  PubMed  Google Scholar 

Fortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernandez, S., Altuna, M., Pegueroles, J., Montal, V., Valldeneu, S., Gimenez, S., Gonzalez-Ortiz, S., Munoz, L., Estelles, T., Illan-Gala, I., Belbin, O., Camacho, V., Wilson, L. R., & Lleo, A. (2020). Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: A cross-sectional study. Lancet, 395(10242), 1988–1997. https://doi.org/10.1016/S0140-6736(20)30689-9

Article  PubMed  PubMed Central  Google Scholar 

Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021). Alzheimer’s disease associated with Down syndrome: A genetic form of dementia. Lancet Neurology, 20(11), 930–942. https://doi.org/10.1016/S1474-4422(21)00245-3

Article  PubMed  Google Scholar 

Gimenez, S., Altuna, M., Blessing, E., Osorio, R. M., & Fortea, J. (2021). Sleep disorders in adults with Down syndrome. J Clin Med, 10(14). https://doi.org/10.3390/jcm10143012

Gimenez, S., Farre, A., Morente, F., Videla, L., Gutierrez, M., Clos, S., Fernandez, A., Blanco, M., Altuna, M., Pegueroles, J., Asensio, A., Benejam, B., Batista, M., Barroeta, I., Fortuna, A., Fortea, J., & Mayos, M. (2022). Feasibility and long-term compliance to continuous positive airway pressure treatment in adults with down syndrome, a genetic form of Alzheimer’s disease. Frontiers in Neuroscience, 16, 838412. https://doi.org/10.3389/fnins.2022.838412

Article  PubMed  PubMed Central  Google Scholar 

Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. C. (2018). Exosomal biomarkers in Down syndrome and Alzheimer’s disease. Free Radical Biology & Medicine, 114, 110–121. https://doi.org/10.1016/j.freeradbiomed.2017.08.028

Article  Google Scholar 

Handen, B. L., Lott, I. T., Christian, B. T., Schupf, N., OBryant, S. Mapstone, M., Fagan, A. M., Lee, J. H., Tudorascu, D., Wang, M. C., Head, E., Klunk, W., Ances, B., Lai, F., Zaman, S., Krinsky-McHale, S., Brickman, A. M., Rosas, H. D., Cohen, A., Andrews, H., Hartley, S., Silverman, W. & Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS). (2020). The Alzheimer’s Biomarker Consortium-Down Syndrome: Rationale and methodology. Alzheimers Dement (Amst), 12(1), e12065. https://doi.org/10.1002/dad2.12065

Article  PubMed  Google Scholar 

Hithersay, R., Baksh, R. A., Startin, C. M., Wijeratne, P., Hamburg, S., Carter, B., Consortium, L., & Strydom, A. (2021). Optimal age and outcome measures for Alzheimer’s disease prevention trials in people with Down syndrome. Alzheimer’s & Dementia, 17(4), 595–604.

Article  Google Scholar 

Illouz, T., Biragyn, A., Frenkel-Morgenstern, M., Weissberg, O., Gorohovski, A., Merzon, E., Green, I., Iulita, F., Flores-Aguilar, L., Dierssen, M., De Toma, I., Lifshitz, H., Antonarakis, S. E., Yu, E., Herault, Y., Potier, M. C., Botte, A., Roper, R., Sredni, B., … Okun, E. (2021a). Specific susceptibility to COVID-19 in adults with Down syndrome. Neuromolecular Medicine, 23(4), 561–571. https://doi.org/10.1007/s12017-021-08651-5

Article  PubMed  PubMed Central  Google Scholar 

Illouz, T., Biragyn, A., Iulita, M. F., Flores-Aguilar, L., Dierssen, M., De Toma, I., Antonarakis, S. E., Yu, E., Herault, Y., Potier, M. C., Botte, A., Roper, R., Sredni, B., London, J., Mobley, W., Strydom, A., & Okun, E. (2021b). Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with down syndrome. Frontiers in Immunology, 12, 621440. https://doi.org/10.3389/fimmu.2021.621440

Article  PubMed